VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce the launch of a feasibility study for the ...

LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today ...

XYZ Media, a leading media company that bridges educational pursuits with technological innovation, is proud to announce the ...

“Bend's proven expertise in formulation and manufacturing complements our innovation and understanding of how to reduce toxicity and improve efficacy of lenalidomide and we're eager to partner with ...

The global Insulin Delivery Device Market, valued at US$32.6 billion in 2024 stood at US$35.3 billion in 2025 and is ...

A traffic stop in Clark County recently resulted in the seizure of 13 boxes of Promethazine. The Arkansas State Police said ...

Merck KGaA has finally claimed an FDA approval for its oral multiple sclerosis therapy Mavenclad, eight years after being turned down by the US regulator. The US approval for relapsing/remitting ...

Novo Nordisk gets CHMP backing for oral GLP-1 agonist Rybelsus in its marketing battle with Eli Lilly, plus positive opinions for Bayer’s diabetes drug Nubeqa, Emergent’s cholera vaccine, and more ...

Inflammatory Bowel Disease Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook ​2025-2035​ The repor ...

Injection of a hydrogel loaded with drugs with simultaneous anti-inflammatory and tissue regenerating properties can be an effective treatment for promoting periodontal regeneration in periodontitis.

The collaboration leverages LTS's background in technology transfer, scale-up, and manufacturing, providing Nualtis with resources to scale their OTF products and deliver them to patients worldwide.